The Study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale

American Heart Journal

Volumn 164, Issue 5, 2012, Pages

  Melloni, Chiara ^a   Sprecher, Dennis L ^b   Sarov Blat, Lea ^b   Patel, Manesh R ^a   Heitner, John F ^c   Hamm, Christian W ^d   Aylward, Philip ^e   Tanguay, Jean Francois ^f   Dewinter, Robbert J ^g   Marber, Michael S ^h   Lerman, Amir ⁱ   Hasselblad, Vic ^a   Granger, Christopher B ^a   Newby, L Kristin ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NEW YORK METHODIST HOSPITAL   (United States)

^d KERCKHOFF HEART CENTER   (Germany)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f MONTREAL HEART INSTITUTE   (Canada)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; LOSMAPIMOD; NITROPRUSSIDE SODIUM; PLACEBO; TROPONIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY FLOW RESERVE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEART VENTRICLE; HUMAN; INFLAMMATION; INVASIVE PROCEDURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; VASODILATATION;

EID: 84868602480     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.07.030     Document Type: Article

References (35)

1. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - executive summary: areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction):developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons J Am Coll Cardiol 50 2007 652 726
2. P. Libby Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
3. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
4. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
5. M. Weber, and C. Hamm Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine Heart 92 2006 843 849
6. R.J. Hoefen The role of MAP kinases in endothelial activation Vascul Pharmacol 38 2002 271 273
7. S. Kumar, J. Boehm, and J.C. Lee p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases Nat Rev Drug Discov 2 2003 717 726
8. X.L. Ma, S. Kumar, and F. Gao Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion Circulation 99 1999 1685 1691
9. M.S. Marber, B. Rose, and Y. Wang The p38 mitogen-activated protein kinase pathway - a potential target for intervention in infarction, hypertrophy, and heart failure J Mol Cell Cardiol 51 2011 485 490
10. Z. Li, J.Y. Ma, and I. Kerr Selective inhibition of p38α MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury Am J Physiol Heart Circ Physiol 291 2006 H1972 H1977
11. C. Hu, A. Dandapat, and L. Sun Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts J Biol Chem 283 2008 10226 10231
12. M. Bellahcene, S. Jacquet, and X.B. Cao Activation of p38 mitogen-activated protein kinase contributes to the early cardiodepressant action of tumor necrosis factor J Am Coll Cardiol 48 2006 545 555
13. L. Sarov-Blat, J.M. Morgan, and P. Fernandez Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans Arterioscler Thromb Vasc Biol 30 2010 2256 2263
14. J. Cheriyan, A.J. Webb, and L. Sarov-Blat Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia Circulation 123 2011 515 523
15. N. Mewton, E. Bonnefoy, and D. Revel Presence and extent of cardiac magnetic resonance microvascular obstruction in reperfused non-ST-elevated myocardial infarction and correlation with infarct size and myocardial enzyme release Cardiology 113 2009 50 58
16. J.C. Lee, S. Kumar, and D.E. Griswold Inhibition of p38 MAP kinase as a therapeutic strategy Immunopharmacology 47 2000 185 201
17. O. Tenhunen, J. Rysa, and M. Ilves Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 mitogen-activated protein kinase in the heart Circ Res 99 2006 485 493
18. P.H. Sugden, and A. Clerk Stress-responsive mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium Circ Res 83 1998 345 352
19. T.A. Fischer, S. Ludwig, and E. Flory Activation of cardiac c-Jun NH(2)-terminal kinases and p38-mitogen-activated protein kinases with abrupt changes in hemodynamic load Hypertension 37 2001 1222 1228
20. D.W. Hommes, M.P. Peppelenbosch, and S.J. van Deventer Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets Gut 52 2003 144 151
21. J.C. Lee, S. Kassis, and S. Kumar p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials Pharmacol Ther 82 1999 389 397
22. J.B. Morris, A.R. Olzinski, and R.E. Bernard p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment Arterioscler Thromb Vasc Biol 28 2008 265 271
23. W. Wu, A. Muchir, and J. Shan Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene Circulation 123 2011 53 61
24. S. Vahebi, A. Ota, and M. Li p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity Circ Res 100 2007 408 415
25. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease [published online ahead of print November 16, 2011]. J Clin Pharmacoldoi:10.1177/0091270010397050.
26. M. Elkhawad, J. Rudd, and L. Sarov-Blat Inhibition of p38 mitogen-activated protein kinase attenuates vascular and systemic inflammation in patients with atherosclerosis as assessed by 18-F fluorodeoxyglucose PET-CT Circulation 122 2010 A16936
27. M. Almagor, A. Keren, and S. Banai Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease Am Heart J 145 2003 248 253
28. H.W. Kim, A. Farzaneh-Far, and R.J. Kim Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications J Am Coll Cardiol 55 2009 1 16
29. A. Hirayama, H. Kusuoka, and H. Yamamoto Serial changes in plasma brain natriuretic peptide concentration at the infarct and non-infarct sites in patients with left ventricular remodelling after myocardial infarction Heart 91 2005 1573 1577
30. W. Bao, D.J. Behm, and S.S. Nerurkar Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production J Cardiovasc Pharmacol 49 2007 362 368
31. H.W. Kim, A. Farzaneh-Far, and R.J. Kim Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications J Am Coll Cardiol 55 2009 1 16
32. M.R. Patel, S.G. Worthley, and A. Stebbins Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial J Am Coll Cardiol Intv 3 2010 52 60
33. R. Kim How we perform delayed enhancement imaging J Cardiovasc Magn Reson 5 2003 505 514
34. B. Sievers, M. Elliott, and L. Hurwitz Rapid detection of myocardial infarction by subsecond, free-breathing delayed contrast-enhancement cardiovascular magnetic resonance Circulation 115 2007 236 244
35. J.W. Weinsaft, H.W. Kim, and D.J. Shah Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction J Am Coll Cardiol 52 2008 148 157